Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Ototoxicity 2Liver Neoplasms 2Hepatoblastoma 2Testicular Neoplasms 1Teratoma 1Sarcoma 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Osteosarcoma 1Neuroblastoma 1Medulloblastoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 45Carboplatin 40Cisplatin 36Paclitaxel 29Nivolumab 24Pemetrexed 24Gemcitabine 23Dexamethasone 21Rituximab 18Ipilimumab 16Cyclophosphamide 15Capecitabine 14Fluorouracil 14Docetaxel 13atezolizumab 13Lenalidomide 12Trastuzumab 12durvalumab 12trastuzumab deruxtecan 12Cytarabine 11daratumumab 11130-nm albumin-bound paclitaxel 10Bevacizumab 10Bortezomib 10Prednisone 10olaparib 10Doxorubicin 9Crizotinib 8Oxaliplatin 8venetoclax 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × sodium thiosulfate × Clear all
NCT00716976 2023-11-09

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Children's Oncology Group

Phase 3 Completed
131 enrolled 18 charts 1 FDA
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Ovarian Germ Cell Cancer, Ototoxicity, Brain Neoplasms, Liver Neoplasms, Medulloblastoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Hepatoblastoma

NCT00652132 2018-05-29

SIOPEL6

University of Birmingham

Phase 3 Completed
116 enrolled 1 FDA
Gastrointestinal

Ototoxicity, Liver Neoplasms, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡